Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables

 
• By Alaric DeArment

The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.

Merck announced the initiation of its Phase III program for oral PCSK9 inhibitor MK-0616 • Source: Shutterstock

More from Clinical Trials

More from R&D